1-anilino-8-naphthalenesulfonate has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 4 studies
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd
8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The induced expression of ATGL leads to increased lipolysis and a decrease in lipid droplet content and bioavailability of neutral lipid." | 1.91 | BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells. ( Chirico, M; Ciarrocchi, A; Gugnoni, M; Iorio, E; Pisanu, ME; Pistoni, M; Rossi, T; Torricelli, F; Zamponi, R, 2023) |
| " Our study implicates a targeted strategy for solid tumors, including breast, brain, pancreatic and ovarian, whereby small, orally bioavailable molecules targeting LIPA block protein folding, induce ER stress and result in tumor cell death." | 1.72 | Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress. ( Ahn, JM; Arteaga, CL; Blatt, EB; Chang, A; Chen, L; Hsieh, M; Kumar, S; Lee, TK; Li, M; Lippincott-Schwartz, J; Liu, X; Liu, Z; Ma, S; Moore, A; Parra, K; Peng, Y; Pratap, UP; Raj, GV; Reese, TC; Roggero, CM; Sareddy, GR; Tan, Z; Tekmal, RR; Vadlamudi, RK; Viswanadhapalli, S; Weintraub, ST; Xu, Z; Yan, H; Zhao, Y, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, X | 1 |
| Viswanadhapalli, S | 1 |
| Kumar, S | 1 |
| Lee, TK | 1 |
| Moore, A | 1 |
| Ma, S | 1 |
| Chen, L | 1 |
| Hsieh, M | 1 |
| Li, M | 1 |
| Sareddy, GR | 1 |
| Parra, K | 1 |
| Blatt, EB | 1 |
| Reese, TC | 1 |
| Zhao, Y | 1 |
| Chang, A | 1 |
| Yan, H | 1 |
| Xu, Z | 1 |
| Pratap, UP | 1 |
| Liu, Z | 1 |
| Roggero, CM | 1 |
| Tan, Z | 1 |
| Weintraub, ST | 1 |
| Peng, Y | 1 |
| Tekmal, RR | 1 |
| Arteaga, CL | 1 |
| Lippincott-Schwartz, J | 1 |
| Vadlamudi, RK | 1 |
| Ahn, JM | 1 |
| Raj, GV | 1 |
| Rossi, T | 1 |
| Zamponi, R | 1 |
| Chirico, M | 1 |
| Pisanu, ME | 1 |
| Iorio, E | 1 |
| Torricelli, F | 1 |
| Gugnoni, M | 1 |
| Ciarrocchi, A | 1 |
| Pistoni, M | 1 |
| Lo, PK | 2 |
| Yao, Y | 2 |
| Zhou, Q | 2 |
| Lee, JS | 1 |
| Zhang, Y | 1 |
| Huang, W | 1 |
| Kane, MA | 1 |
4 other studies available for 1-anilino-8-naphthalenesulfonate and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress.
Topics: Animals; Endoplasmic Reticulum Stress; Humans; Lipase; Mice; Protein Folding; Triple Negative Breast | 2022 |
BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells.
Topics: Acyltransferases; Cell Line, Tumor; Fatty Acids; Humans; Lipase; Lipids; Proteins; Reactive Oxygen S | 2023 |
Inhibition of LIPG phospholipase activity suppresses tumor formation of human basal-like triple-negative breast cancer.
Topics: Benzoates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug | 2020 |
LIPG signaling promotes tumor initiation and metastasis of human basal-like triple-negative breast cancer.
Topics: Carcinogenesis; Cell Movement; Cell Proliferation; Cytokines; Epithelial-Mesenchymal Transition; Hum | 2018 |